- Home
- VEL vs EVMN Comparison
VEL vs EVMN Comparison
Compare VEL & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | EVMN |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.4M | 628.9M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VEL | EVMN |
|---|---|---|
| Price | $19.80 | $19.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.75 | ★ $39.33 |
| AVG Volume (30 Days) | 76.1K | ★ 173.3K |
| Earning Date | 11-06-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.26 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $229,360,000.00 | $13,000,000.00 |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $27.31 | N/A |
| P/E Ratio | $8.04 | ★ N/A |
| Revenue Growth | 116.81 | ★ 160.00 |
| 52 Week Low | $16.12 | $13.89 |
| 52 Week High | $20.98 | $24.03 |
Technical Indicators
Market Signals| Indicator | VEL | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 60.30 | N/A |
| Support Level | $19.12 | N/A |
| Resistance Level | $20.15 | N/A |
| Average True Range (ATR) | 0.59 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 63.08 | 0.00 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.